Dr. Haas on the Role of PSMA in Prostate Cancer

Video

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program, associate professor of medicine, Hospital of the University of Pennsylvania, discusses the role of prostate-specific membrane antigen (PSMA) in prostate cancer.

PSMA is an antigen expressed on the cell surface that offers an important target for prostate cancer therapy, Haas says.

PSMA is not only a viable target in prostate cancer, Haas adds. Neovascular PSMA expression is common in several other tumor types.

In prostate cancer, as castrate resistance develops, PSMA is overexpressed. As such, patients with castration-resistant disease have more PSMA than patients with early-stage disease, Haas concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS